Abstract
Introduction
Colon cancers diagnosed in the interval after a complete colonoscopy may occur due to limitations of colonoscopy or due to rapid tumor growth. The aim of this study was to compare the association of BRAF V600E mutation in interval versus non-interval colorectal cancers and to determine the relationship between BRAF mutation and 5-year survival.
Methods
We searched our institution’s cancer registry for interval cancers, defined as colon cancers that developed within 5 years of a complete colonoscopy. These were frequency matched to patients with non-interval cancers. Archived cancer specimens were tested for BRAF V600E mutation and MSI.
Results
There were 63 interval and 131 non-interval cancers. BRAF mutation was present in 28% of interval cancers compared to 19% of non-interval cancers (P = 0.18). In a multivariable logistic regression model, proximal location (OR 1.85; 95% CI 1.01–3.8) and MSI (OR 2.7; 95% 1.1–6.8) were independently associated with interval cancers while BRAF mutation was not (OR 0.93; 95% CI 0.36–2.38). BRAF mutation portended a poor 5-year survival, particularly among microsatellite stable cancers.
Conclusions
BRAF mutation is not associated with interval cancers but is a marker of poor prognosis, particularly in microsatellite stable cancers.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005;65:6063–6069.
Vilkin A, Niv Y, Nagasaka T, et al. Microsatellite instability, MLH1 promoter methylation, and BRAF mutation analysis in sporadic colorectal cancers of different ethnic groups in Israel. Cancer. 2009;115:760–769.
Sawhney MS, Farrar WD, Gudiseva S, et al. Microsatellite instability in interval colon cancers. Gastroenterology. 2006;131:1700–1705.
Ogino S, Meyerhardt JA, Kawasaki T, et al. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch. 2007;450:529–537.
Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2008;58:90–96.
Ferracin M, Gafa R, Miotto E, et al. The methylator phenotype in microsatellite stable colorectal cancers is characterized by a distinct gene expression profile. J Pathol. 2008;214:594–602.
Hawkins N, Norrie M, Cheong K, et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology. 2002;122:1376–1387.
Lee S, Cho NY, Choi M, Yoo EJ, Kim JH, Kang GH. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. Pathol Int. 2008;58:104–113.
Acknowledgments
Supported in part by grants from the VA Career Development Award (A. Shaukat) and Minnesota Veterans Research Institute (A. Shaukat).
Financial disclosures
None for all the authors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shaukat, A., Arain, M., Thaygarajan, B. et al. Is BRAF Mutation Associated with Interval Colorectal Cancers?. Dig Dis Sci 55, 2352–2356 (2010). https://doi.org/10.1007/s10620-010-1182-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-010-1182-9